Clinical trial

ASCEND-1: Lifestyle Intervention Plus Mazdutide for Weight Management

Recruiting now · Not applicable · 1 countries · Registry ID NCT07517042

Recruiting nowNot applicableInterventional

What this study is about

Obesity is a chronic, progressive, and relapsing disease. Although lifestyle interventions and anti-obesity medications are effective for inducing weight loss, evidence regarding their role in long-term weight maintenance after pharmacologically induced weight reduction remains limited. In addition, the high cost and potential adverse effects of weight-loss medications restrict their prolonged use, and it is unclear whether low dose medication, intensive life style intervention or together can serve as an effective strategy for weight maintenance. This randomized controlled trial aims to evaluate the effectiveness of a 1-year intensive lifestyle intervention, a reduced dose of mazdutide (3.0 mg once weekly), or their combination in weight maintenance among individuals with obesity who have achieved initial weight loss after intensive treatment with high dose mazdutide. The study seeks to provide high-quality clinical evidence to inform long-term weight maintenance strategies after weight loss in patients with obesity.

A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.

Basic eligibility

Age18 Years to Not listed
SexAll
Healthy volunteersNot accepted
ConditionObesity, Weight Control

Full registry criteria

Inclusion Criteria: * Adult men or women aged 18 years or older; * Simple obesity, defined as a body mass index (BMI) of 28.0-45.0 kg/m²; * Able and willing to provide written informed consent. Exclusion Criteria: * Active pulmonary tuberculosis, malignant tumors, human immunodeficiency virus (HIV) infection, or other serious infectious or systemic diseases; * Severe hepatic impairment (aspartate aminotransferase \[AST\] or alanine aminotransferase \[ALT\] \>3 times the upper limit of normal), severe renal impairment, or end-stage renal disease (estimated glomerular filtration rate \[eGFR\] \<30 mL/min/1.73 m²); * Severe cardiovascular diseases, including angina pectoris, myocardial infarction, or stroke within the past 6 months; * Severe gastrointestinal diseases, or a history of gastrointestinal resection surgery within the past year; * Acute or chronic pancreatitis, gallbladder disease, or pancreatic injury; * Obesity secondary to other causes, including Cushing's syndrome, primary hypothyroidism, hypothalamic obesity, or acromegaly; drug-induced obesity, such as obesity related to the use of antipsychotic agents or glucocorticoids; * Current smoker or habitual smoking within the past 3 months; * Current use of other weight-loss medications or a history of bariatric surgery; * Previously diagnosed diabetes mellitus or current use of glucose-lowering medications; * Pregnant or breastfeeding women, or women planning pregnancy during the study period; * Inability to complete a 2-year follow-up due to health conditions, relocation, or other reasons; * Any other condition deemed by the investigator to make the participant unsuitable for participation in the study.

Treatments and study arms

Mazdutide

Drug

Mazdutide is administered subcutaneously at 3.0 mg once weekly for 52 weeks during the weight maintenance period.

Intensive Lifestyle Intervention

Behavioral

A structured intensive lifestyle intervention including individualized dietary counseling, physical activity guidance, and behavioral modification support for 52 weeks during the weight maintenance period.

Primary outcomes

Percentage change of body weightFrom randomization to Week 52

Study locations

13 locations were listed when this page was built. The first 40 are shown.

The Second Affiliated Hospital of Chongqing Medical University🇨🇳 Chongqing, Chongqing Municipality, China
Dongfang Liu, MDContact
Dongfang Liu, MDPrincipal Investigator
Fujian Provincial Hospital, Affiliated to Fuzhou University🇨🇳 Fuzhou, Fujian, China
Gang Chen, MDContact
Gang Chen, MDPrincipal Investigator
Zhejiang Provincial People's Hospital🇨🇳 Hangzhou, Zhejiang, China
Xiaohong Wu, MDContact
Xiaohong Wu, MDPrincipal Investigator
The Affiliated Hospital of Southwest Medical University🇨🇳 Luzhou, Sichuan, China
Yong Xu, MDContact
Yong Xu, MDPrincipal Investigator
Nanjing First Hospital, Nanjing Medical University🇨🇳 Nanjing, Jiangsu, China
Qian Li, MDContact
Qian Li, MDPrincipal Investigator
Huadong Hospital, Fudan University🇨🇳 Shanghai, Shanghai Municipality, China
Bin Lu, PhDContact
Bin Lu, PhDPrincipal Investigator
Renji Hospital, Shanghai Jiao Tong University School of Medicine🇨🇳 Shanghai, Shanghai Municipality, China
Jing Ma, PhDContact
Jing Ma, PhDPrincipal Investigator
Shanghai Tenth People's Hospital, School of Medicine, Tongji University🇨🇳 Shanghai, Shanghai Municipality, China
Shen Qu, PhDContact
Shen Qu, PhDPrincipal Investigator
Zhongshan Hospital, Fudan University🇨🇳 Shanghai, Shanghai Municipality, China
JINGJING JIANG, MD, PhDContact
HUIJIE ZHANG, MD, PhDPrincipal Investigator
The Affiliated Suzhou Science and Technology Town Hospital of Nanjing Medical University🇨🇳 Suzhou, Jiangsu, China
Zhimin Ma, MDContact
Zhimin Ma, MDPrincipal Investigator
The First Affiliated Hospital of Wenzhou Medical University🇨🇳 Wenzhou, Zhejiang, China
Hong Zhu, MDContact
Hong Zhu, MDPrincipal Investigator
Zhongnan Hospital of Wuhan University🇨🇳 Wuhan, Hubei, China
Zhe Dai, MDContact
Zhe Dai, MDPrincipal Investigator
The First Affiliated Hospital of Xiamen University🇨🇳 Xiamen, Fujian, China
Xin Zheng, MDContact
Changqin Liu, MDPrincipal Investigator